Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Celcuity (NASDAQ:CELC) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

Other equities research analysts have also issued research reports about the company. Leerink Partners set a $155.00 price target on Celcuity in a research report on Tuesday, June 2nd. Needham & Company LLC cut their price target on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. Craig Hallum reiterated a “buy” rating and issued a $178.00 price target on shares of Celcuity in a report on Wednesday, July 15th. Citizens Jmp increased their price objective on shares of Celcuity from $160.00 to $177.00 and gave the stock a “market outperform” rating in a research report on Wednesday, July 15th. Finally, Wells Fargo & Company dropped their price objective on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $153.64.

Celcuity Stock Performance

NASDAQ CELC opened at $92.00 on Friday. Celcuity has a 12 month low of $44.42 and a 12 month high of $151.02. The stock has a 50-day simple moving average of $93.88 and a 200 day simple moving average of $108.41. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.49 billion, a PE ratio of -21.40 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Research analysts forecast that Celcuity will post -3.76 EPS for the current year.

Institutional Investors Weigh In On Celcuity

Hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the period. US Bancorp DE boosted its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the period. Parallel Advisors LLC acquired a new position in Celcuity in the 1st quarter valued at about $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity in the 4th quarter valued at about $42,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.